IRIS
ANGARANO, Gioacchino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.893
AS - Asia 9.392
EU - Europa 6.887
SA - Sud America 2.743
AF - Africa 433
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 12
AN - Antartide 2
Totale 43.378
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.652
SG - Singapore 3.879
BR - Brasile 2.208
CN - Cina 2.118
DE - Germania 1.513
HK - Hong Kong 1.502
SE - Svezia 872
UA - Ucraina 831
IT - Italia 785
RU - Federazione Russa 753
FI - Finlandia 654
VN - Vietnam 558
FR - Francia 552
GB - Regno Unito 465
IN - India 317
AR - Argentina 187
BD - Bangladesh 162
IQ - Iraq 124
CI - Costa d'Avorio 120
ID - Indonesia 102
ZA - Sudafrica 97
CA - Canada 93
EC - Ecuador 86
MX - Messico 86
TR - Turchia 80
CO - Colombia 73
PK - Pakistan 73
BE - Belgio 69
SA - Arabia Saudita 65
VE - Venezuela 65
IE - Irlanda 58
JP - Giappone 56
PL - Polonia 55
MA - Marocco 51
UZ - Uzbekistan 47
ES - Italia 46
PY - Paraguay 43
NL - Olanda 41
TN - Tunisia 37
PH - Filippine 34
CL - Cile 33
KE - Kenya 33
AT - Austria 32
JO - Giordania 32
MK - Macedonia 27
IR - Iran 26
EG - Egitto 22
MY - Malesia 22
AE - Emirati Arabi Uniti 20
IL - Israele 20
NP - Nepal 19
AZ - Azerbaigian 18
ET - Etiopia 17
PE - Perù 16
UY - Uruguay 16
KZ - Kazakistan 14
LB - Libano 14
LT - Lituania 13
OM - Oman 13
PS - Palestinian Territory 13
RO - Romania 13
RS - Serbia 13
BG - Bulgaria 12
BO - Bolivia 12
CR - Costa Rica 11
CZ - Repubblica Ceca 11
GE - Georgia 11
GR - Grecia 11
HR - Croazia 11
JM - Giamaica 11
TH - Thailandia 11
AU - Australia 10
DZ - Algeria 10
EU - Europa 10
BY - Bielorussia 9
NG - Nigeria 9
AL - Albania 8
HN - Honduras 8
KW - Kuwait 8
BH - Bahrain 7
DO - Repubblica Dominicana 7
NI - Nicaragua 7
CH - Svizzera 6
HU - Ungheria 6
LY - Libia 6
PT - Portogallo 6
SN - Senegal 6
AO - Angola 5
XK - ???statistics.table.value.countryCode.XK??? 5
PA - Panama 4
QA - Qatar 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BB - Barbados 3
BW - Botswana 3
KH - Cambogia 3
KR - Corea 3
LV - Lettonia 3
SV - El Salvador 3
Totale 43.326
Salva come PNG Salva come JPEG
Città #
Fairfield 2.714
Ashburn 2.012
Singapore 2.001
Woodbridge 1.990
Jacksonville 1.861
Chandler 1.710
Houston 1.499
Hong Kong 1.483
Seattle 1.120
San Jose 1.061
Wilmington 1.004
Cambridge 909
Ann Arbor 840
Nyköping 579
Beijing 483
Dallas 466
Lawrence 466
Roxbury 464
Nanjing 448
Lauterbourg 413
New York 333
Des Moines 292
Boardman 280
Los Angeles 256
Princeton 232
Helsinki 202
São Paulo 184
Ho Chi Minh City 173
Santa Clara 128
Shenyang 128
Bari 125
Buffalo 121
Abidjan 120
Hebei 120
Hanoi 119
Inglewood 119
Munich 113
San Diego 113
Dearborn 111
Nanchang 110
Brooklyn 97
Council Bluffs 83
London 74
Jiaxing 73
Rio de Janeiro 71
Tianjin 69
Dublin 57
Rome 56
Baghdad 53
Brussels 53
Tokyo 53
Falkenstein 52
Milan 49
Dong Ket 46
Jakarta 46
Moscow 46
Belo Horizonte 45
Guangzhou 45
Pune 45
Curitiba 44
Brasília 43
Warsaw 43
Changsha 38
Chicago 38
Frankfurt am Main 38
Johannesburg 38
Tashkent 38
Orem 37
Paris 36
Denver 31
Atlanta 30
Chennai 30
New Delhi 30
Hefei 29
Montreal 29
Salvador 29
Mexico City 28
Nairobi 28
Porto Alegre 28
Taranto 28
Amman 27
Campinas 27
Dhaka 27
Guayaquil 27
Stockholm 27
Nuremberg 26
Asunción 25
Da Nang 25
Mumbai 25
San Francisco 25
Caracas 24
Quito 24
Riyadh 24
Jeddah 23
The Dalles 23
Toronto 23
Turku 23
Washington 23
Auburn Hills 22
Boston 22
Totale 29.220
Salva come PNG Salva come JPEG
Nome #
Anemia as a risk factor for disease progression in patients admitted for COVID-19: data from a large, multicenter cohort study 400
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals 369
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 365
Economic evaluation of HIV treatments: The I.CO.N.A. cohort study 235
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 221
Access to health services for undocumented immigrants in Apulia. 206
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 203
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates 194
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage 186
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? 185
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 185
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 183
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. 177
Access to HAART in HIV-Infected Immigrants: A Retrospective Multicenter Italian Study 174
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 172
An outbreak of HIV-1 BC recombinants in Southern Italy 171
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia 167
Sphingomonas paucimobilis outbreak in a dialysis room: Case report and literature review of an emerging healthcare associated infection 162
Cryptosporidiosis in the acquired immunodeficiency syndrome: a case report 157
Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. 156
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients 156
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 156
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. 155
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 155
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 154
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection 154
A cyanobacterium-like body found in the stools of an HIV+ patient with diarrhoea 153
" INFEZIONI DA CLAMYDIA PNEUMONIAE IN PAZIENTI CON A.I.D.S. " 153
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. 153
Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC 153
The elderly and direct antiviral agents: Constraint or challenge? 152
Prevalence of urinary schistosomiasis in migrants in Apulia, a region of southern Italy, in the years 2006-2016 152
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio 151
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 151
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 151
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study 150
Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio 149
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 149
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 149
Improved virological outcome in non-B patients: a possible role for baseline coreceptor tropism 148
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 147
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 146
Co-receptor switch during HAART is independent of virological success 145
Access to Health Services for Undocumented Immigrants in Apulia 141
Limiting severe outcomes and impact on intensive care units of moderate-intermediate 2009 pandemic influenza: role of infectious diseases units. 140
Alterazioni oftalmoscopiche e fluorangiografiche in pazienti affetti da AIDS 139
Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection 139
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies 139
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL 139
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 138
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 136
Incidence of tuberculosis among HIV-Infected patients receiving highly active antiretroviral therapy in Europe and North America 136
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents 135
Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin 134
Persistence of e antigen as prognostic marker in acute hepatitis B 133
Splenic abscesses as a first manifestation of Crohn's disease: A case report 133
A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient 132
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 132
Intrathecal immune response in human immunodeficiency virus infection 131
Are the proposed env mutations actually associated with resistance to maraviroc? 129
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients 129
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 129
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR 128
Evolution of antiretroviral prescription and response over a period of 8 years: An Italian multicentre observational prospective cohort study 128
Long-term efficacy and safety of switching from lamivudine + adefovir to tenofovir disoproxil fumarate in virologically suppressed patients 128
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). 128
Epidemiological multicentric Italian society of infectious and tropical diseases study on prevalence of tropical diseases in hospitalized immigrants in Italy during 2002 127
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic 126
Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors 126
Pulmonary Artery Filling Defects in Covid-19 Patients Revealed Using CT Pulmonary Angiography: A Predictable Complication? 126
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples 125
Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens 125
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 125
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART 125
Adherence of hiv patients switching to emtricitabina+tenofovir disoproxil+rilpivirin. Real world evidence from italian administrative databases 124
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 124
Parkinsonism in a patient with AIDS and cerebral opportunistic granulomatous lesions 123
Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection 123
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 123
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study 122
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years 122
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients 122
Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study 122
Hepatitis B virus markers, alpha-fetoprotein and survival in fulminant viral hepatitis 121
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir 121
Reduced concentrations of HIV-RNA and TNF-alpha coexist in CSF of AIDS patients with progressive multifocal leukoencephalopathy 120
Frequent cervicovaginal shedding of HIV-1 in asymptomatic, non-severely immunodeficient women 120
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 119
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 119
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 119
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 119
Gaining back what is lost: recovering the sense of smell in mild to moderate patients after COVID-19 119
Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections 118
Risk of AIDS in HIV seroconverters: a comparison between intravenous drug users and homosexual males 118
HIV-1 variability and progression to AIDS: a longitudinal study 118
Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects 117
Association between HIV p24 antigen in cerebrospinal fluid and severe complications in the central nervous system 117
Immunological markers in HIV-infected pregnant and non-pregnant women 117
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort 116
"In vitro" spontaneous production of B-chemokines by endocervical and endometrial short-term bioptic cultures 115
Totale 14.949
Salva come PNG Salva come JPEG
Categoria #
all - tutte 176.521
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.521
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021968 0 0 0 0 0 0 0 0 0 536 249 183
2021/20222.793 111 370 36 232 137 183 103 196 183 170 452 620
2022/20234.452 799 318 186 449 634 519 39 504 776 34 102 92
2023/20241.502 144 343 83 75 95 394 39 39 28 41 30 191
2024/20256.274 89 117 690 215 110 544 333 557 278 323 937 2.081
2025/202611.584 1.853 726 1.097 1.552 1.312 750 1.545 401 1.243 1.105 0 0
Totale 44.037